Eligible trials needed to compare SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin) with GLP-1 RAs (e.g., semaglutide, liraglutide) or include either class compared to placebo, provided they reported cardiovascular or renal outcomes such as MACE, heart failure hospitalizations, cardiovascular death, or changes in renal function (e.g., eGFR decline). This evidence concerns the gene GCG and heart failure.